降低INSC的表达水平预测结肠癌患者的预后不佳
Yan Li1, Shugao Tian1, Jing Ran2
1Molecular Biology Laboratory, Chongqing Medical and Pharmaceutical College, Chongqing, China.
概括
可注射螺杆定向适配蛋白 (INSC) 的下调与较差的结肠癌结局有关. INSC可以作为预测患者存活率的新型预后生物标志物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物标志物发现发现
背景情况:
- 结肠癌 (CC) 的预后仍然是一个挑战,需要新的生物标志物.
- 在细胞分裂中的可注射螺旋方向适配蛋白 (INSC) 功能表明在癌症中的潜在作用.
研究的目的:
- 调查INSC在结肠癌中的预后价值.
- 评估INSC作为一种潜在的诊断和预后生物标志物.
主要方法:
- 使用公共数据库对INSC mRNA水平的分析.
- 通过免疫组织化学评估INSC蛋白表达.
- 与临床病理特征和患者存活率的相关性分析.
- 开发一种基于INSC的诺米图,用于预测预后.
主要成果:
- 与正常组织相比,INSC在结肠癌组织中的mRNA和蛋白质水平显著下调.
- 低INSC水平与高级TNM阶段,T阶段和N阶段相关.
- 减少INSC表达与较短的整体存活率 (OS) 和疾病特异性存活率有关.
- INSC蛋白表达被确定为OS的独立预后因素.
- 基于INSC的诺米图表显示,与TNM分期相比,在5年后的OS中,预后准确度更高.
结论:
- INSC下调与不良的临床病理特征和结肠癌的结果有关.
- INSC代表了结肠癌潜在的新型独立预后生物标志物.
- 基于INSC的诺米图可能会改善结肠癌预后的预测.
相关概念视频
Non-LTR Retrotransposons
11.6K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.6K
Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Cancer Survival Analysis
381
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
381


